Last reviewed · How we verify
NCT03234764
Longitudinal Follow-up Study for Food Allergies
trial testing Immunotherapy in Food Allergy in 166 participants. Completed in 18 December 2017.
18 December 2017
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 166 |
| Start date | 1 March 2016 |
| Primary completion | 18 December 2017 |
| Estimated completion | 18 December 2017 |
Drugs / interventions tested
- Immunotherapy — full drug profile →
Conditions studied
- Food Allergy — all drugs for Food Allergy →
Sponsor
Stanford University
Who can join
Adults 6 Months to 70, any sex, with Food Allergy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the clinical usefulness of assessing specific human allergy antibodies and other immunologic parameters associated with the diagnosis, evolution, and management of allergic disease.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab.
Andorf S, Manohar M, Dominguez T, Block W, et al · · 2017 · cited 30× · PMID 29296107 · DOI 10.1186/s13223-017-0223-8 -
Feasibility of sustained response through long-term dosing in food allergy immunotherapy.
Andorf S, Manohar M, Dominguez T, Block W, et al · · 2017 · cited 11× · PMID 29296108 · DOI 10.1186/s13223-017-0224-7
Verify or expand the search:
- PubMed search for NCT03234764
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immunotherapy
Trials testing the same drug.
- NCT07293247 — A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After · Phase 2 · not yet recruiting
- NCT07259473 — Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
- NCT07297030 — SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer · Phase 2 · not yet recruiting
- NCT07231575 — Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC · Phase 2 · not yet recruiting
Other recruiting trials for Food Allergy
Currently open trials in the same condition.
- NCT07210320 — PK/PD Study of IN-001 Sublingual Spray in Healthy Adults · Phase 1 · recruiting
- NCT06943534 — Omalizumab Weight-Based Dosing Efficacy Trial · Phase 2 · recruiting
- NCT06872996 — Trophallergen Prick Tests (PT) : Influence of Food Sample Shelf Life on the Reproducibility of PT Results · NA · recruiting
- NCT06529913 — Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases · NA · recruiting
- NCT06558526 — Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients · NA · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03234764 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 19 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03234764.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing